Secondary amyloidosis occurs in 5% of patients with poorly controlled, slow-developing
chronic inflammatory diseases, mainly rheumatoid arthritis or spondyloarthropathies.
1
Unless the activity of the underlying disease can be effectively controlled, the
development of secondary amyloidosis is associated with a poor prognosis and reduces
the survival rate of these patients.
2
Until now, therapeutic approaches have yielded poor results, with the exception of
alkylating agents. However, the high toxicity of these drugs often complicates patient
management. Tumor necrosis factor-alpha antagonists are changing the clinical course
of some inflammatory diseases, but experience in patients with secondary amyloidosis
is scarce.
3
,
4
,
5
,
6
,
7
,
8
The aim of our study was to assess the efficacy and safety of anti-tumor necrosis
factor agents in a series of 25 Spanish patients with amyloidosis secondary to a rheumatic
disease.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Diagnosis and treatment of amyloidosis.Ann Rheum Dis. 1997; 56: 631-633
- Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland.Rheumatology (Oxford). 1999; 38: 499-503
- Benefit of anti-TNF alpha treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis (letter).Ann Rheum Dis. 2003; 62: 368-369
- Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab.Arthritis Rheum. 2002; 46: 2571-2573
- Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome (letter).N Engl J Med. 2000; 343: 1044-1045
- Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides.Arthritis Rheum. 2003; 48: 2019-2024
- Resolution with etanercept of nephrotic syndrome due to renal AA amyloidosis in adult Still’s disease (letter).Am J Med. 2003; 115: 589-590
- Treatment of renal amyloidosis in rheumatoid arthritis requires further investigation.Arthritis Rheum. 2003; 48 (author reply 3299–3300): 3299
- Anti-TNF treatment in secondary amyloidosis (letter).Rheumatology (Oxford). 2003; 42: 1425-1426
- Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.N Engl J Med. 2000; 343: 1594-1602
- Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate.Lancet. 1999; 354: 1932-1939
- Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis.Arthritis Rheum. 2003; 48: 2224-2233
- Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.J Immunol. 1999; 163: 1521-1528
- TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide.J Am Soc Nephrol. 1998; 9: 433-438
- Presentation, survival and prognostic markers in AA amyloidosis.QJM. 2000; 93: 535-542
- Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis.Eur Heart J. 2002; 23: 157-161
- Secondary systemic amyloidosis.Medicine (Baltimore). 1991; 70: 246-256
- Ten years’ experience of an amyloid clinic—a clinicopathological survey.Q J Med. 1985; 54: 213-227
- Renal amyloidosis—a fourteen-year follow-up.Q J Med. 1973; 42: 15-40
Article info
Identification
Copyright
© 2005 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- ErrataThe American Journal of MedicineVol. 119Issue 2
- PreviewSeshadri P, Iqbal N, Stern L, Williams M, Chicano KL, Daily DA, McGrory J, Gracely EJ, Rader DJ, Samaha FF. A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am J Med. 2004;117:298-405.
- Full-Text
- Preview
